Hepatitis viruses B (HBV) and C (HCV) are major causes of liver diseases worldwide generally and in developing countries specifically. More than 70 million of the world population is estimated to be infected with hepatitis C virus. The World Health organization (WHO) has planned to eliminate HCV from the globe by the year 2030 [1]. Similarly estimated 240 million people were infected by HBV by 2005 globally [2].

  With the advent of direct acting antiviruses it is possible to cure hepatitis C virus [3]. The aforementioned WHO plan can only be achieved if the effective direct acting antiviruses are distributed in an equitable and affordable ways. Though there is no cure to hepatitis B virus currently its untoward consequences can be significantly alleviated by using effective antiviruses in those who require treatment [4].

  The treatment cost of the anti-hepatitis C virus medications varies depending on the manufacturer. Treatment of HCV is believed to be cost effective [5,6]. However, if one from a developing country agrees to take the HCV eradication therapy he or she may be obliged to sell important personal assets [7]. This is an obstacle for the poor as selling an asset could compromise the basic needs of the individual and the family.

  Similarly, there are various options for the treatment of hepatitis B virus infection. Tenofovir is one of the drugs used in the treatment of hepatitis B virus; however it too is costly and difficult to access especially in developing countries.

  To halt the untoward consequences of these deadly hepatitis viruses, their treatment shall be made available in affordable prices for those who require it. Likewise, if the WHO is to achieve its goal the treatments shall be made available to the poor on a reasonable price.

  To halt the untoward consequences of these deadly hepatitis vi-ruses, their treatment shall be made available in affordable prices for those who require it. Likewise, if the WHO is to achieve its goal the treatments shall be made available to the poor on a reasonable price.

References

1. Polaris Observatory HCV Collaborators. “Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study”. The Lancet Gastroenterology and Hepatology 3 (2017): 161-176.
2. Ott JJ., et al. “Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity”. Vaccine12 (2012): 2212-2219.
3. Wei B., et al. “Systematic review and meta-analysis: real-world effectiveness of direct-acting antiviral therapies in chronic hepatitis C genotype 3 in Asia”. BMJ Open Gastroenterology 1 (2018): e000209.
4. Vlachogiannakos J and Papatheodoridis GV. “Hepatitis B: Who and when to treat?” Liver International 1 (2018): 71-78.
5. Chaillon A., et al. “Cost-effectiveness and budgetary impact of HCV treatment with direct-acting antivirals in India including the risk of reinfection”. PLoS One6 (2019): e0217964.
6. Marcellusi A., et al. “Early Treatment in HCV: Is it a Cost-Utility Option from the Italian Perspective?” Clinical Drug Investigation 8 (2016): 661-672.
7. Paltiel O., et al. “Sell an ox” - the price of cure for hepatitis C in two countries”. International Journal of Health Policy and Management (2020): 10.

Citation

Citation: Oumer Abdu Muhie and Habtewold Shibru . “The Role of Oxidative Stress and Antioxidant Effects in Female Endometriosis: A Systematic Review”. Acta Scientific Gastrointestinal Disorders 4.4 (2021): 01-02.

Copyright

Copyright: © 2021 Oumer Abdu Muhie and Habtewold Shibru. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.